Elicio Therapeutics, Inc. (ELTX) stock
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.06 (-3.85%)
Close on Nov 13, 2026Market cap $39.42MP/E –Yield –
Elicio Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Elicio Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $23.54M, down 22.9% year over year. For fiscal 2025 it was $24.90M, down 26.0% from the year before. The highest annual figure on record is $48.70M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.90M | -26.0% |
| FY2024 | Dec 31, 2024 | $33.66M | +41.1% |
| FY2023 | Dec 31, 2023 | $23.85M | +31.7% |
| FY2022 | Dec 31, 2022 | $18.10M | -62.8% |
| FY2021 | Dec 31, 2021 | $48.70M | +24.9% |
| FY2020 | Dec 31, 2020 | $38.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.89M | -3.0% |
| Q2 FY2026 | Jun 30, 2026 | $6.81M | -2.8% |
| Q1 FY2026 | Mar 31, 2026 | $6.76M | -13.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.08M | -52.6% |
| Q3 FY2025 | Sep 30, 2025 | $5.04M | -30.1% |
| Q2 FY2025 | Jun 30, 2025 | $7.01M | -14.4% |
| Q1 FY2025 | Mar 31, 2025 | $7.78M | +2.9% |
| Q4 FY2024 | Dec 31, 2024 | $10.71M | +73.9% |
| Q3 FY2024 | Sep 30, 2024 | $7.21M | -0.8% |
| Q2 FY2024 | Jun 30, 2024 | $8.18M | +65.5% |
| Q1 FY2024 | Mar 31, 2024 | $7.56M | +37.8% |
| Q4 FY2023 | Dec 31, 2023 | $6.16M | +43.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.26M | +58.2% |
| Q2 FY2023 | Jun 30, 2023 | $4.94M | -1.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.48M | -53.0% |
| Q4 FY2022 | Dec 31, 2022 | $4.29M | -35.7% |
| Q3 FY2022 | Sep 30, 2022 | $4.59M | -65.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.04M | -65.1% |
| Q1 FY2022 | Mar 31, 2022 | $11.67M | -18.4% |
| Q4 FY2021 | Dec 31, 2021 | $6.67M | -39.7% |
| Q3 FY2021 | Sep 30, 2021 | $13.29M | +118.3% |
| Q2 FY2021 | Jun 30, 2021 | $14.44M | +18.1% |
| Q1 FY2021 | Mar 31, 2021 | $14.30M | +49.0% |
| Q4 FY2020 | Dec 31, 2020 | $11.07M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.09M | – |
| Q2 FY2020 | Jun 30, 2020 | $12.23M | – |
| Q1 FY2020 | Mar 31, 2020 | $9.60M | – |
See a number that looks wrong?